Claims for Patent: 8,420,645

Summary for Patent: 8,420,645

Title:	Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,- 4]triazin-2-yl]benzamide and processes related to preparing the same
Abstract:	The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin- -2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-- 2-yl]benzamide, and salts thereof.
Inventor(s):	Weng; Lingkai (Malvern, PA), Qiao; Lei (Downingtown, PA), Zhou; Jiacheng (Newark, DE), Liu; Pingli (Newark, DE), Pan; Yongchun (Newark, DE)
Assignee:	Incyte Corporation (Wilmington, DE)
Application Number:	12/469,360
Patent Claims:	1. A salt which is 2-fluoro-N-methyl-4-[7-(quinolin-6- ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide dihydrochloric acid salt, or a hydrate or solvate thereof. 2. A hydrate of the salt of claim 1. 3. The hydrate of claim 2, which is characterized by a melting point of about 220 to about 224.degree. C. 4. The hydrate of claim 2, which is characterized by a melting point of about 222.degree. C. 5. The hydrate of claim 2, which is crystalline. 6. The hydrate of claim 2 having a DSC thermogram which is characterized by an endothermic peak at about 222.degree. C. 7. The hydrate of claim 2, having a DSC thermogram substantially as shown in FIG. 2. 8. The hydrate of claim 2, having a TGA substantially as shown in FIG. 3. 9. The hydrate of claim 2, having an X-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2.theta. at about 26.0. 10. The hydrate of claim 2, having an X-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2.theta. at about 24.7. 11. The hydrate of claim 2, having an X-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2.theta. at about 18.2. 12. The hydrate of claim 2, having an X-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2.theta. at about 29.3. 13. The hydrate of claim 2, having an X-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2.theta. at about 7.8. 14. The hydrate of claim 2, having an X-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2.theta. at about 26.0 and 24.7. 15. The hydrate of claim 2, having an X-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2.theta. at about 26.0, 24.7, 18.2, 29.3, and 7.8 16. A composition comprising the salt, or a hydrate or solvate thereof, of claim 1 and at least one pharmaceutically acceptable carrier.